OneMedNet Corporation announced a partnership with Inka Health, a wholly‑owned subsidiary of Onco‑Innovations, to provide U.S. oncology real‑world data through OneMedNet’s iRWD platform powered by Palantir Foundry. The collaboration was disclosed on April 1 2026 and will give Inka Health access to OneMedNet’s regulatory‑grade, AI‑ready imaging data to accelerate development timelines and support evidence generation for Onco‑Innovations’ PNKP Inhibitor Technology targeting PTEN/SHP1‑deficient cancers.
The partnership will allow Inka Health to use OneMedNet’s platform to identify patient responders, expand indications beyond advanced metastatic colorectal cancer, and generate complementary evidence to inform clinical and regulatory decision‑making. Inka Health’s SynoGraph AI platform will be integrated with the iRWD data to predict treatment outcomes across multimodal medical data sets, while the Palantir Foundry backbone will enable scalable, AI‑augmented cohort discovery.
OneMedNet’s financial context underscores the strategic importance of the deal. The company reported $1.36 million in revenue over the last twelve months, a 111 % year‑over‑year increase, and record bookings for 2025 totaling $2.79 million in contract value—more than four times the previous fiscal year. Despite these growth metrics, OneMedNet faces financial headwinds that have prompted management to focus on cost discipline and revenue diversification through partnerships such as this one.
Aaron Green, CEO of OneMedNet, said, "This collaboration demonstrates exactly what our iRWD platform was designed to do—find and characterize rare, high‑value patient populations to accelerate innovation." Thomas O'Shaughnessy, CEO of Onco‑Innovations, added, "Access to U.S. oncology real‑world data enables the company to better understand patient populations with PTEN/SHP1‑deficient tumors and explore additional indications."
The deal positions OneMedNet to deepen its foothold in the oncology data market, while providing Inka Health with a robust data foundation to de‑risk its PNKP Inhibitor pipeline and improve capital efficiency. By leveraging Palantir Foundry’s AI capabilities, the partnership is expected to accelerate the identification of responder cohorts and support evidence generation that could shorten development timelines and reduce regulatory risk for both companies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.